Skip to main content
Top
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer

Authors: Judy A King, Fang Tan, Flaubert Mbeunkui, Zachariah Chambers, Sarah Cantrell, Hairu Chen, Diego Alvarez, Lalita A Shevde, Solomon F Ofori-Acquah

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Activated leukocyte cell adhesion molecule (ALCAM) is implicated in the prognosis of multiple cancers with low level expression associated with metastasis and early death in breast cancer. Despite this significance, mechanisms that regulate ALCAM gene expression and ALCAM's role in adhesion of pre-metastatic circulating tumor cells have not been defined. We studied ALCAM expression in 20 tumor cell lines by real-time PCR, western blot and immunochemistry. Epigenetic alterations of the ALCAM promoter were assessed using methylation-specific PCR and bisulfite sequencing. ALCAM's role in adhesion of tumor cells to the vascular wall was studied in isolated perfused lungs.

Results

A common site for transcription initiation of the ALCAM gene was identified and the ALCAM promoter sequenced. The promoter contains multiple cis-active elements including a functional p65 NF-κB motif, and it harbors an extensive array of CpG residues highly methylated exclusively in ALCAM-negative tumor cells. These CpG residues were modestly demethylated after 5-aza-2-deoxycytidine treatment. Restoration of high-level ALCAM expression using an ALCAM cDNA increased clustering of MDA-MB-435 tumor cells perfused through the pulmonary vasculature of ventilated rat lungs. Anti-ALCAM antibodies reduced the number of intravascular tumor cell clusters.

Conclusion

Our data suggests that loss of ALCAM expression, due in part to DNA methylation of extensive segments of the promoter, significantly impairs the ability of circulating tumor cells to adhere to each other, and may therefore promote metastasis. These findings offer insight into the mechanisms for down-regulation of ALCAM gene expression in tumor cells, and for the positive prognostic value of high-level ALCAM in breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bruder SP, Ricalton NS, Boynton RE, Connolly TJ, Jaiswal N, Zaia J, Barry FP: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res. 1998, 13: 655-663. 10.1359/jbmr.1998.13.4.655CrossRefPubMed Bruder SP, Ricalton NS, Boynton RE, Connolly TJ, Jaiswal N, Zaia J, Barry FP: Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res. 1998, 13: 655-663. 10.1359/jbmr.1998.13.4.655CrossRefPubMed
2.
go back to reference Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995, 181: 2213-2220. 10.1084/jem.181.6.2213CrossRefPubMed Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995, 181: 2213-2220. 10.1084/jem.181.6.2213CrossRefPubMed
3.
go back to reference Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S: DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron. 1991, 7: 209-220. 10.1016/0896-6273(91)90259-3CrossRefPubMed Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S: DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron. 1991, 7: 209-220. 10.1016/0896-6273(91)90259-3CrossRefPubMed
4.
go back to reference Kanki JP, Chang S, Kuwada JY: The molecular cloning and characterization of potential chick DM-GRASP homologs in zebrafish and mouse. J Neurobiol. 1994, 25: 831-845. 10.1002/neu.480250708CrossRefPubMed Kanki JP, Chang S, Kuwada JY: The molecular cloning and characterization of potential chick DM-GRASP homologs in zebrafish and mouse. J Neurobiol. 1994, 25: 831-845. 10.1002/neu.480250708CrossRefPubMed
5.
go back to reference Konno A, Ahn JS, Kitamura H, Hamilton MJ, Gebe JA, Aruffo A, Davis WC: Tissue distribution of CD6 and CD6 ligand in cattle: expression of the CD6 ligand (CD166) in the autonomic nervous system of cattle and the human. J Leukoc Biol. 2001, 69: 944-950.PubMed Konno A, Ahn JS, Kitamura H, Hamilton MJ, Gebe JA, Aruffo A, Davis WC: Tissue distribution of CD6 and CD6 ligand in cattle: expression of the CD6 ligand (CD166) in the autonomic nervous system of cattle and the human. J Leukoc Biol. 2001, 69: 944-950.PubMed
6.
go back to reference Laessing U, Giordano S, Stecher B, Lottspeich F, Stuermer CA: Molecular characterization of fish neurolin: a growth-associated cell surface protein and member of the immunoglobulin superfamily in the fish retinotectal system with similarities to chick protein DM-GRASP/SC-1/BEN. Differentiation. 1994, 56: 21-29.CrossRefPubMed Laessing U, Giordano S, Stecher B, Lottspeich F, Stuermer CA: Molecular characterization of fish neurolin: a growth-associated cell surface protein and member of the immunoglobulin superfamily in the fish retinotectal system with similarities to chick protein DM-GRASP/SC-1/BEN. Differentiation. 1994, 56: 21-29.CrossRefPubMed
7.
go back to reference Paschke KA, Lottspeich F, Stuermer CA: Neurolin, a cell surface glycoprotein on growing retinal axons in the goldfish visual system, is reexpressed during retinal axonal regeneration. J Cell Biol. 1992, 117: 863-875. 10.1083/jcb.117.4.863CrossRefPubMed Paschke KA, Lottspeich F, Stuermer CA: Neurolin, a cell surface glycoprotein on growing retinal axons in the goldfish visual system, is reexpressed during retinal axonal regeneration. J Cell Biol. 1992, 117: 863-875. 10.1083/jcb.117.4.863CrossRefPubMed
8.
go back to reference Peduzzi JD, Irwin MH, Geisert EE: Distribution and characteristics of a 90 kDa protein, KG-CAM, in the rat CNS. Brain Res. 1994, 640: 296-307. 10.1016/0006-8993(94)91885-6CrossRefPubMed Peduzzi JD, Irwin MH, Geisert EE: Distribution and characteristics of a 90 kDa protein, KG-CAM, in the rat CNS. Brain Res. 1994, 640: 296-307. 10.1016/0006-8993(94)91885-6CrossRefPubMed
9.
go back to reference Pourquie O, Corbel C, Le Caer JP, Rossier J, Le Douarin NM: BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA. 1992, 89: 5261-5265. 10.1073/pnas.89.12.5261PubMedCentralCrossRefPubMed Pourquie O, Corbel C, Le Caer JP, Rossier J, Le Douarin NM: BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA. 1992, 89: 5261-5265. 10.1073/pnas.89.12.5261PubMedCentralCrossRefPubMed
10.
go back to reference Prince JT, Nishiyama A, Healy PA, Beasley L, Stallcup WB: Expression of the F84.1 glycoprotein in the spinal cord and cranial nerves of the developing rat. Brain Res Dev Brain Res. 1992, 68: 193-201. 10.1016/0165-3806(92)90061-ZCrossRefPubMed Prince JT, Nishiyama A, Healy PA, Beasley L, Stallcup WB: Expression of the F84.1 glycoprotein in the spinal cord and cranial nerves of the developing rat. Brain Res Dev Brain Res. 1992, 68: 193-201. 10.1016/0165-3806(92)90061-ZCrossRefPubMed
11.
go back to reference Stephan JP, Bald L, Roberts PE, Lee J, Gu Q, Mather JP: Distribution and function of the adhesion molecule BEN during rat development. Dev Biol. 1999, 212: 264-277. 10.1006/dbio.1999.9348CrossRefPubMed Stephan JP, Bald L, Roberts PE, Lee J, Gu Q, Mather JP: Distribution and function of the adhesion molecule BEN during rat development. Dev Biol. 1999, 212: 264-277. 10.1006/dbio.1999.9348CrossRefPubMed
12.
go back to reference Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland KC, Kohr B, Lee A, Phillips HS, Shelton DL: Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron. 1991, 7: 535-545. 10.1016/0896-6273(91)90366-8CrossRefPubMed Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland KC, Kohr B, Lee A, Phillips HS, Shelton DL: Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron. 1991, 7: 535-545. 10.1016/0896-6273(91)90366-8CrossRefPubMed
13.
go back to reference van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, Figdor CG, Swart GW: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001, 276: 25783-25790. 10.1074/jbc.M011272200CrossRefPubMed van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, Figdor CG, Swart GW: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001, 276: 25783-25790. 10.1074/jbc.M011272200CrossRefPubMed
14.
go back to reference Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, Swart GW: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998, 152: 805-813.PubMedCentralPubMed Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, Swart GW: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998, 152: 805-813.PubMedCentralPubMed
15.
go back to reference van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000, 156: 769-774.PubMedCentralCrossRefPubMed van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000, 156: 769-774.PubMedCentralCrossRefPubMed
16.
go back to reference Zheng X, Ding W, Xie L, Chen Z: Expression and significance of activated leukocyte cell adhesion molecule in prostatic intraepithelial neoplasia and adenocarcinoma. Zhonghua Nan Ke Xue. 2004, 10: 265-268.PubMed Zheng X, Ding W, Xie L, Chen Z: Expression and significance of activated leukocyte cell adhesion molecule in prostatic intraepithelial neoplasia and adenocarcinoma. Zhonghua Nan Ke Xue. 2004, 10: 265-268.PubMed
17.
go back to reference Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 2003, 54: 34-43. 10.1002/pros.10161CrossRefPubMed Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 2003, 54: 34-43. 10.1002/pros.10161CrossRefPubMed
18.
go back to reference Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 2005, 68: 462-470. 10.1159/000086989CrossRefPubMed Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 2005, 68: 462-470. 10.1159/000086989CrossRefPubMed
19.
go back to reference Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004, 57: 1160-1164. 10.1136/jcp.2004.016238PubMedCentralCrossRefPubMed Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004, 57: 1160-1164. 10.1136/jcp.2004.016238PubMedCentralCrossRefPubMed
20.
go back to reference Tomita K, van Bokhoven A, Jansen CFJ, Kiemeney LA, Karthaus HFM, Vriesema J, Bussemakers MJG, Witjes JA, Schalken JA: Activated leukocyte cell adhesion molecule (ALCAM) expression is associated with a poor prognosis for bladder cancer patients. UroOncology. 2003, 3: 121-129. 10.1080/15610950310001632322.CrossRef Tomita K, van Bokhoven A, Jansen CFJ, Kiemeney LA, Karthaus HFM, Vriesema J, Bussemakers MJG, Witjes JA, Schalken JA: Activated leukocyte cell adhesion molecule (ALCAM) expression is associated with a poor prognosis for bladder cancer patients. UroOncology. 2003, 3: 121-129. 10.1080/15610950310001632322.CrossRef
21.
go back to reference Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009, 101: 457-464. 10.1038/sj.bjc.6605136PubMedCentralCrossRefPubMed Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009, 101: 457-464. 10.1038/sj.bjc.6605136PubMedCentralCrossRefPubMed
22.
go back to reference Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008, 151: 122-128. 10.1016/j.trsl.2007.09.006CrossRefPubMed Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008, 151: 122-128. 10.1016/j.trsl.2007.09.006CrossRefPubMed
23.
go back to reference King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG: Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004, 6: R478-487. 10.1186/bcr815PubMedCentralCrossRefPubMed King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG: Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004, 6: R478-487. 10.1186/bcr815PubMedCentralCrossRefPubMed
24.
go back to reference Davies SR, Dent C, Watkins G, King JA, Mokbel K, Jiang WG: Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep. 2008, 19: 555-561.PubMed Davies SR, Dent C, Watkins G, King JA, Mokbel K, Jiang WG: Expression of the cell to cell adhesion molecule, ALCAM, in breast cancer patients and the potential link with skeletal metastasis. Oncol Rep. 2008, 19: 555-561.PubMed
25.
go back to reference Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006, 12: BR245-256.PubMed Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006, 12: BR245-256.PubMed
26.
go back to reference Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006, 59: 403-409. 10.1136/jcp.2005.028209PubMedCentralCrossRefPubMed Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006, 59: 403-409. 10.1136/jcp.2005.028209PubMedCentralCrossRefPubMed
27.
go back to reference Kilic E, Milde-Langosch K, Muller V, Wirtz R, Ihnen M: Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy. Pathologe. 2008, 29 (Suppl 2): 347-352. 10.1007/s00292-008-1080-5CrossRefPubMed Kilic E, Milde-Langosch K, Muller V, Wirtz R, Ihnen M: Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy. Pathologe. 2008, 29 (Suppl 2): 347-352. 10.1007/s00292-008-1080-5CrossRefPubMed
28.
go back to reference Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008, 112: 419-427. 10.1007/s10549-007-9879-yCrossRefPubMed Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008, 112: 419-427. 10.1007/s10549-007-9879-yCrossRefPubMed
30.
go back to reference Al-Mehdi AB, Tozawa K, Fisher A, Shientag L, Lee A, Muschel R: Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 2000, 6: 100-101. 10.1038/71429CrossRefPubMed Al-Mehdi AB, Tozawa K, Fisher A, Shientag L, Lee A, Muschel R: Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 2000, 6: 100-101. 10.1038/71429CrossRefPubMed
31.
go back to reference Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al-Mehdi AB: Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol. 2002, 161: 749-753.PubMedCentralCrossRefPubMed Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al-Mehdi AB: Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol. 2002, 161: 749-753.PubMedCentralCrossRefPubMed
32.
go back to reference Zhang G, Slaughter C, Humphries EH: v-rel Induces ectopic expression of an adhesion molecule, DM-GRASP, during B-lymphoma development. Mol Cell Biol. 1995, 15: 1806-1816.PubMedCentralCrossRefPubMed Zhang G, Slaughter C, Humphries EH: v-rel Induces ectopic expression of an adhesion molecule, DM-GRASP, during B-lymphoma development. Mol Cell Biol. 1995, 15: 1806-1816.PubMedCentralCrossRefPubMed
33.
go back to reference Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R: Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005, 97: 1507-1515. 10.1093/jnci/dji312CrossRefPubMed Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R: Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005, 97: 1507-1515. 10.1093/jnci/dji312CrossRefPubMed
34.
go back to reference Borner C, Schlagbauer Wadl H, Fellay I, Selzer E, Polterauer P, Jansen B: Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 1999, 9: 347-350. 10.1097/00008390-199908000-00002CrossRefPubMed Borner C, Schlagbauer Wadl H, Fellay I, Selzer E, Polterauer P, Jansen B: Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 1999, 9: 347-350. 10.1097/00008390-199908000-00002CrossRefPubMed
35.
go back to reference Celebi JT, Shendrik I, Silvers DN, Peacocke M: Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet. 2000, 37: 653-657. 10.1136/jmg.37.9.653PubMedCentralCrossRefPubMed Celebi JT, Shendrik I, Silvers DN, Peacocke M: Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet. 2000, 37: 653-657. 10.1136/jmg.37.9.653PubMedCentralCrossRefPubMed
36.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766CrossRefPubMed Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W: Mutations of the BRAF gene in human cancer. Nature. 2002, 417: 949-954. 10.1038/nature00766CrossRefPubMed
37.
go back to reference Ikeda K, Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 2004, 279: 55315-55323. 10.1074/jbc.M407776200CrossRefPubMed Ikeda K, Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 2004, 279: 55315-55323. 10.1074/jbc.M407776200CrossRefPubMed
38.
go back to reference Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004, 103: 1635-1640. 10.1182/blood-2003-03-0687CrossRefPubMed Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004, 103: 1635-1640. 10.1182/blood-2003-03-0687CrossRefPubMed
39.
go back to reference Seniski GG, Camargo AA, Ierardi DF, Ramos EA, Grochoski M, Ribeiro ES, Cavalli IJ, Pedrosa FO, de Souza EM, Zanata SM: ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009, 9: 80- 10.1186/1471-2407-9-80PubMedCentralCrossRefPubMed Seniski GG, Camargo AA, Ierardi DF, Ramos EA, Grochoski M, Ribeiro ES, Cavalli IJ, Pedrosa FO, de Souza EM, Zanata SM: ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009, 9: 80- 10.1186/1471-2407-9-80PubMedCentralCrossRefPubMed
40.
go back to reference Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65: 10692-10699. 10.1158/0008-5472.CAN-05-1277CrossRefPubMed Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65: 10692-10699. 10.1158/0008-5472.CAN-05-1277CrossRefPubMed
41.
go back to reference Jezierska A, Matysiak W, Motyl T: ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 2006, 12: BR263-273.PubMed Jezierska A, Matysiak W, Motyl T: ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 2006, 12: BR263-273.PubMed
42.
go back to reference Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006, 12: BR245-256.PubMed Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006, 12: BR245-256.PubMed
43.
go back to reference Davies S, Jiang WG: ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res. 2010, 30: 1163-1168.PubMed Davies S, Jiang WG: ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis. Anticancer Res. 2010, 30: 1163-1168.PubMed
44.
go back to reference Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Janicke F, Briassoulis E: Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer. 2010, Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Janicke F, Briassoulis E: Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer. 2010,
45.
go back to reference Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP: Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer. 2009, 125: 9-14. 10.1002/ijc.24292PubMedCentralCrossRefPubMed Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP: Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer. 2009, 125: 9-14. 10.1002/ijc.24292PubMedCentralCrossRefPubMed
46.
go back to reference De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997, 183: 404-411. 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9CrossRefPubMed De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997, 183: 404-411. 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9CrossRefPubMed
47.
go back to reference Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, Ofori-Acquah SF: Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006, 580: 2637-2645. 10.1016/j.febslet.2006.04.013CrossRefPubMed Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, Ofori-Acquah SF: Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006, 580: 2637-2645. 10.1016/j.febslet.2006.04.013CrossRefPubMed
48.
go back to reference Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA, Samant RS: Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer. 2009, 125: 556-564. 10.1002/ijc.24276CrossRefPubMed Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA, Samant RS: Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer. 2009, 125: 556-564. 10.1002/ijc.24276CrossRefPubMed
49.
go back to reference Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS: Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res. 2008, 10: R22- 10.1186/bcr1874PubMedCentralCrossRefPubMed Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS: Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res. 2008, 10: R22- 10.1186/bcr1874PubMedCentralCrossRefPubMed
50.
go back to reference Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis. 2006, 23: 123-133. 10.1007/s10585-006-9013-2PubMedCentralCrossRefPubMed Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis. 2006, 23: 123-133. 10.1007/s10585-006-9013-2PubMedCentralCrossRefPubMed
51.
go back to reference Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ: Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis. 2000, 18: 683-693. 10.1023/A:1013124725690CrossRefPubMed Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ: Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis. 2000, 18: 683-693. 10.1023/A:1013124725690CrossRefPubMed
52.
go back to reference Chetham PM, Babal P, Bridges JP, Moore TM, Stevens T: Segmental regulation of pulmonary vascular permeability by store-operated Ca2+ entry. Am J Physiol. 1999, 276: L41-50.PubMed Chetham PM, Babal P, Bridges JP, Moore TM, Stevens T: Segmental regulation of pulmonary vascular permeability by store-operated Ca2+ entry. Am J Physiol. 1999, 276: L41-50.PubMed
53.
go back to reference Alvarez DF, King JA, Weber D, Addison E, Liedtke W, Townsley MI: Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res. 2006, 99: 988-995. 10.1161/01.RES.0000247065.11756.19PubMedCentralCrossRefPubMed Alvarez DF, King JA, Weber D, Addison E, Liedtke W, Townsley MI: Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res. 2006, 99: 988-995. 10.1161/01.RES.0000247065.11756.19PubMedCentralCrossRefPubMed
Metadata
Title
Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer
Authors
Judy A King
Fang Tan
Flaubert Mbeunkui
Zachariah Chambers
Sarah Cantrell
Hairu Chen
Diego Alvarez
Lalita A Shevde
Solomon F Ofori-Acquah
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-266

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine